Purdue Pharma and the Sackler family who own the company have proposed a new $7.4 billion settlement to resolve thousands of ...

BV100 is a new formulation of rifabutin suitable for intravenous administration, which BioVersys claims offers a new ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

The ranges were 4.5 to nine years for men and 6.5 to 11 years for women, according to the researchers, who have published ...

President Trump's pick to lead the Department of Health and Human Services (HHS), Robert F Kennedy Jr, will be scrutinised at ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a conversation focused on rare liver disease primary biliary cholangitis (PBC ...

In Part 5 of our Life Sciences Industry Report, we turn our attention to the oncological field of research and development, from cancer therapies to cancer care, from clinical trials to the patient’s ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...